Entecavir Market Report 2026

Entecavir Market Overview

• Entecavir market size has reached to $0.74 billion in 2025 • Expected to grow to $0.9 billion in 2030 at a compound annual growth rate (CAGR) of 4.1% • Growth Driver: Rising Hepatitis B Prevalence Driving The Growth Of The Market • Market Trend: Advancements In Clinical Trials And Innovative Drug Development For Chronic Hepatitis B Treatment • Asia-Pacific was the largest region in 2025 and North America is the fastest growing region.

What Is Covered Under Entecavir Market?

Entecavir is an antiviral drug prescribed for managing chronic hepatitis B. It functions by blocking the replication of the hepatitis B virus, thereby lowering the viral load. This helps reduce the chances of severe liver damage and complications such as cirrhosis or liver cancer. The main product types of entecavir are tablets and oral solution. Entecavir tablets are taken orally and are prescribed for the treatment of chronic hepatitis B (CHB) infection. These are used for various applications such as hepatitis B treatment, liver transplantation, and others. These are distributed through various distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Entecavir Market Growth Forecast?

The entecavir market size is expected to see steady growth in the next few years. It will grow to $0.9 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to growth in chronic hepatitis b patient pool, rising access to antiviral therapies in emerging markets, increasing adoption of long-term viral suppression strategies, expansion of public health hepatitis programs, growing demand for affordable generics. Major trends in the forecast period include rising long-term antiviral therapy adoption, increasing focus on chronic hepatitis b management, growing demand for oral antiviral medications, expansion of generic entecavir availability, increased monitoring of viral load suppression.

Global Entecavir Market Segmentation

1) By Product Type: Tablets, Oral Solution 2) By Application: Hepatitis B Treatment, Liver Transplantation, Other Applications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Tablets: Standard Dose Tablets, High Dose Tablets 2) By Oral Solution: Ready-to-Use Liquid Solution, Powder For Oral Solution

What Are The Drivers Of The Entecavir Market?

The increasing prevalence of hepatitis B is expected to propel the growth of the entecavir market going forward. Hepatitis B refers to a viral infection that affects the liver, causing jaundice, fatigue, and abdominal pain, and can lead to chronic liver disease or liver cancer if left untreated. The increase in hepatitis B cases is attributed to factors such as unprotected sexual contact, sharing of needles, mother-to-child transmission during childbirth, and insufficient vaccination coverage in certain regions. Entecavir helps treat hepatitis B by inhibiting the replication of the hepatitis B virus (HBV) DNA, reducing viral load and preventing liver damage. For instance, in August 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2023, non-Hispanic Asian/Pacific Islander individuals had a rate of newly reported chronic hepatitis B cases that was nearly 10 times higher than that of non-Hispanic White individuals. Therefore, the increasing prevalence of hepatitis B is driving the growth of the entecavir industry. The rising healthcare expenditure is expected to propel the growth of the entecavir market going forward. Healthcare expenditure refers to the total financial resources spent on medical goods and services to maintain and improve population health. Healthcare expenditure is rising because an aging population requires more frequent medical care and long-term health services. Higher healthcare expenditure is useful for entecavir uptake because increased national spending on antiviral treatment and chronic disease management supports broader access to hepatitis B therapies. For instance, in April 2025, according to the Office for National Statistics, a UK-based government department, between 2023 and 2024, total healthcare spending increased by 6.5% in nominal terms, and by 2.4% in real terms after accounting for inflation. Therefore, the rising healthcare expenditure is expected to propel the growth of the entecavir industry.

Key Players In The Global Entecavir Market

Major companies operating in the entecavir market are Bristol-Myers Squibb Company, GSK plc, Teva Pharmaceutical Industries Ltd., Qingfeng Pharmaceutical Group, Aurobindo Pharma Ltd., ScinoPharm Taiwan Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Zhejiang Huahai Pharmaceuticals Co. Ltd., Qianjin Group, Genix Pharma Ltd., Dawnrays Pharmaceutical Holidings Ltd., Zhejiang Ausun Pharmaceutical Co. Ltd., Hunan Warrant Chiral Pharmaceutical Co. Ltd., Camber Pharmaceuticals Inc., Century Pharmaceuticals Ltd., Aligos Therapeutics Inc. , HRV Global Life Sceince, Solco Healthcare LLC, Accela ChemBio Inc.

Global Entecavir Market Trends and Insights

Major companies operating in the entecavir market are developing innovative drugs through clinical trial to enhance the efficacy and treatment outcomes for patients with chronic hepatitis B, potentially reducing resistance and improving long-term viral suppression. Clinical trials are research studies conducted to evaluate the safety, efficacy, and potential side effects of new treatments, drugs, or therapies in human participants. For instance, in October 2024, Aligos Therapeutics Inc., a US-based biotechnology company is undergoing phase 2 clinical trial for ALG-000184 for the treatment of hepatitis B. ALG-000184 is a type of therapy known as a capsid assembly modulator, which works by disrupting the formation of the capsid, the protective shell surrounding a virus's genetic material. The fourth phase of the study is currently assessing the long-term effects of ALG-000184 (300 mg), either as a standalone treatment or in combination with the approved antiviral entecavir, in patients with chronic hepatitis B. The combination of ALG-000184 and entecavir resulted in more significant reductions in viral load compared to entecavir alone, with ALG-000184 demonstrating similar effectiveness regardless of whether it was used alongside entecavir. The virus remained consistently suppressed throughout the study, both in patients who were HBeAg-positive and HBeAg-negative.

Regional Insights

Asia-Pacific was the largest region in the entecavir market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Entecavir Market?

The entecavir market consists of sales of generic versions, branded formulations, combination therapies, antiviral drugs, injectable formulations and over-the-counter antiviral supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Entecavir Market Report 2026?

The entecavir market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the entecavir industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.